PALI
PALISADE BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.25
+1.63%Oct 20, 2026, 12:05 UTC
PALISADE BIO, INC. reported Phase 1b data for PALI-2108 in a five-patient Crohn's disease cohort, showing a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days.
Source:Oct 12, 2026, 12:05 UTC
PALISADE BIO, INC. presented five sets of clinical, pharmacokinetic, pharmacodynamic and mechanistic data on PALI-2108 at ACG 2026, including two presentations selected for Presidential Poster Awards.
Source:Sep 28, 2026, 12:50 UTC
Palisade Bio announced it will present clinical and translational data for PALI-2108 in ulcerative colitis and Crohn's disease at UEG Week 2026.
Source:Sep 22, 2026, 12:35 UTC
The U.S. FDA cleared Palisade Bio's Investigational New Drug application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD trial in moderate to severe Crohn's disease.
Source:Jun 29, 2026, 12:30 UTC
Palisade Bio received FDA clearance of its Investigational New Drug application for PALI-2108.
Source: